Epcoritamab,rituximab,cyclophosphamide,doxorubicin,vincristine,prednisone,lenalidomide,bendamustine,cytarabine,dexamethasone,oxaliplatin,carboplatin,gemcitabine,ifosfamide
genmab,abbvie
['epcoritamab']
extended follow up at 20mo for epcoritamab in lbcl presented by #17icml with durable responses for those who do achieve cr however worse response rates for hgbl; impressive durations (including post car) but perhaps combination therapy needed for high risk pts 
Heme/Onc fellow @UCCancerCenter interested in aggressive lymphoma, novel therapeutics, and cellular therapies #lymsm #TcellRx. Views are my own.